ConductScience.org, home

Paper21079145

The evolving role of histology in the management of advanced non-small-cell lung cancer.

Langer CJ and 4 others. J Clin Oncol, 2010. Cited by 240 papers, by iCite.

Cite this record

ConductScience Library. The evolving role of histology in the management of advanced non-small-cell lung cancer. Papers, record 21079145. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21079145

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The evolving role of histology in the management of advanced non-small-cell lung cancer.
PubMed
Journal
J Clin Oncol
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
240
iCite
Relative citation ratio, by iCite
5.37
iCite
Revised in PubMed
2022-04-09
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Langer CJCorey J
2Besse BBenjamin
3Gualberto AAntonio
4Brambilla EElizabeth
5Soria JCJean-Charles

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Humans

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT02716038Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLCBackgroundClinicalTrials.gov
NCT05965102Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung CancerBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in21768461Role of cytology in the management of non-small-cell lung cancer.https://conductscience.org/library/papers/21768461

Source PubMed

Download CSV of comments and corrections

Cited by139

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 240 citations.

PMIDTitleJournalYearIn PapersSource
42530663Treatment patterns and outcomes of second/third-line therapy in advanced non-small cell lung cancer with actionable genomic alterations (RECAP).Clin Exp Metastasis2026https://conductscience.org/library/papers/42530663PubMed
41599703Tumor Characterization Using [18F]FDG PET Radiomics in a PD-L1-Positive NSCLC Cohort.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/41599703PubMed
41465456Overexpression of GM3 and Ganglioside Pattern Remodeling in Lung Adenocarcinoma Brain Metastases Identified by Ion Mobility Mass Spectrometry.Int J Mol Sci2025https://conductscience.org/library/papers/41465456PubMed
41378286Long-term outcomes and patterns of failure after empiric SBRT for presumed early-stage lung tumors.Front Oncol2025https://conductscience.org/library/papers/41378286PubMed
41353554Disproportionality analysis of adverse events in advanced lung cancer treated with atezolizumab plus platinum-based combination chemotherapy.J Pharm Health Care Sci2025https://conductscience.org/library/papers/41353554PubMed
41210989Down-regulation of MFNG promotes the metastatic potential of lung adenocarcinoma by regulating TGF-β/Smad signaling.iScience2025https://conductscience.org/library/papers/41210989PubMed
41023740Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer.Cell Commun Signal2025https://conductscience.org/library/papers/41023740PubMed
40938464The functions and regulation of transcription factor YBX1 in cancers.Mol Biol Rep2025https://conductscience.org/library/papers/40938464PubMed
40852643Sonodynamic Therapy-Based DNA Nanocarriers with Hypoxia-Inducible Factor-1α Silencing Activation for Precision Lung Cancer Therapy.Biomater Res2025https://conductscience.org/library/papers/40852643PubMed
40759444
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.
J Immunother Cancer2025https://conductscience.org/library/papers/40759444PubMed
40047406Regulation of lung cancer initiation and progression by the stem cell determinant Musashi.Elife2025https://conductscience.org/library/papers/40047406PubMed
40028322Exosome tropism and various pathways in lung cancer metastasis.Front Immunol2025https://conductscience.org/library/papers/40028322PubMed
39952933One-carbon metabolism is distinct metabolic signature for proliferative intermediate exhausted T cells of ICB-resistant cancer patients.Cell Death Discov2025https://conductscience.org/library/papers/39952933PubMed
39633593TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China.Biomark Med2024https://conductscience.org/library/papers/39633593PubMed
39385301CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma.Cell Biosci2024https://conductscience.org/library/papers/39385301PubMed
38862862Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry.Clin Transl Oncol2024https://conductscience.org/library/papers/38862862PubMed
38827178
First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis.
Ther Adv Med Oncol2024https://conductscience.org/library/papers/38827178PubMed
38679648miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review.J Egypt Natl Canc Inst2024https://conductscience.org/library/papers/38679648PubMed
37859595MicroRNA‑mediated regulation in lung adenocarcinoma: Signaling pathways and potential therapeutic implications (Review).Oncol Rep2023https://conductscience.org/library/papers/37859595PubMed
37612622Network meta-analysis of first-line immune checkpoint inhibitor therapy in advanced non-squamous non-small cell lung cancer patients with PD-L1 expression ≥ 50.BMC Cancer2023https://conductscience.org/library/papers/37612622PubMed

See all 139 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/21079145

GET https://conductscience.org/api/papers/v1/21079145/cited_by?page=2